Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. - Test2 - elhamkhani - TriplyDB

Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.

Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.

http://www.wikidata.org/entity/Q34233774

about

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead Cystic fibrosis therapeutics: the road ahead Inhaled Antibiotics for Gram-Negative Respiratory Infections Clinical experimentation with aerosol antibiotics: current and future methods of administration.Inhaled antibiotics for lower airway infections.Update in cystic fibrosis 2012.Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections Recent advances in the management of cystic fibrosis.Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.Evidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis.Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.Fosfomycin Aerosolized antibiotics: do they add to the treatment of pneumonia?Cystic fibrosis - a multiorgan protein misfolding disease.From pipeline to patient: new developments in cystic fibrosis therapeutics.The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection.Inhaled antibiotics to treat lung infection.Emerging drugs for cystic fibrosis.Enhancing adherence to inhaled therapies in cystic fibrosis.Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients.Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.Aerosolized antibiotics in cystic fibrosis: an update.New perspectives in the management of Pseudomonas aeruginosa infections.The problems of antibiotic resistance in cystic fibrosis and solutions.Aspects of pulmonary drug delivery strategies for infections in cystic fibrosis--where do we stand?Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis.New and Emerging Treatments for Cystic Fibrosis.Inhaled antibiotics in the treatment of non-cystic fibrosis bronchiectasis: clinical and drug delivery perspectives.Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: The current pipeline of therapeutics.Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis.New drug developments in the management of cystic fibrosis lung disease.Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections.Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects.Nebulized antibiotics in mechanically ventilated patients: roadmap and challenges.Blocking peptidoglycan recycling in Pseudomonas aeruginosa attenuates intrinsic resistance to fosfomycin.Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance.

P2860

Q24188054-69DC98CB-1BA1-4C1A-94C7-CD6B087D328D Q26747065-55E7C263-08C0-4FA5-AAA7-76BEA4C51A5D Q26822988-2E19EF88-8D89-4E2B-A87B-8FD04FC7E211 Q27022401-4FF3C13A-BEBA-4E4D-9DE9-C500462A404E Q28386160-34A66DE6-4CCA-4385-B577-70595AE24F24 Q30448377-478F8817-EC64-4D40-96B7-F6CA1CF1A802 Q33640488-ED222069-CFA8-4E9F-A9CF-C8CF1B0D5005 Q33738510-8868642C-B293-4E6D-BA68-9B8E24E12D89 Q33786154-2FBFD251-1832-4564-AC9E-1ABF6684386F Q34427981-28036620-08E3-4DF6-8FAC-F63F543AFE9D Q34921154-249E5816-C2D8-444E-AB95-802F9AA14C19 Q35426622-A0A9FDC1-856A-4889-BD50-1AB5C9C41CA8 Q36627996-6B34FDB9-C0AE-4F05-BE67-040004FCE87D Q36675246-86F62F73-3589-460A-9CB1-6171163E8BBA Q37271774-9CED98F0-9F07-48C0-99CB-BB1732A8DA74 Q37474478-A4D7FAB4-1F77-464A-B0BD-2CF29A8D5E66 Q38078451-7826374A-A2FF-4240-BFC7-F3EDF87103F9 Q38130513-71DFE89A-CFA4-4153-9DBE-A2512891D5A9 Q38162996-D71A95A2-DEAF-4BF5-A12B-D5C4C9D1F232 Q38183476-D1B7BFC9-C3CD-421F-AAD0-032BADB38390 Q38193291-17264BBC-9500-425E-9ECD-B7399214EA2B Q38193537-F55C8163-7D92-4B0C-AEEB-D49E3B90C035 Q38208281-6543C51B-25B1-4411-835C-4A86167A32BC Q38212537-4433BB59-F65A-4F54-A94F-F25BE3C836FD Q38243221-F15B0892-EAA8-4E79-9831-A25130D39C99 Q38300820-B5BC60F4-B54D-45C1-AF99-6E7CFBCE17F8 Q38340865-8AA4EBB3-BB8A-4283-99FB-DF8F210E522B Q38447194-C9CD196D-5DEB-40D0-93A7-21810DA4B9B7 Q38532426-4B23A732-B7F4-44EA-9543-2ADEBE967F32 Q38569772-55557F3B-9C96-4876-8D97-0D4B8C50A316 Q38579967-A991DC6B-117E-4440-BDD9-619A411FBCA6 Q38634682-0459A59E-3002-447F-943E-2720FA375857 Q38635530-C97DAF22-5057-47A8-A5B6-1AA92553D77D Q38790382-2705EB27-F747-4918-989B-1E9B08C48D65 Q38821019-251145CD-956C-4AF9-B248-2135BD79159D Q38859870-98D05569-2C7F-4E14-BF10-0ABF4C7E1A64 Q40121090-5A49C2AF-3CB1-4C57-B5C1-40A67654D3AD Q40422166-9C08CE0E-8110-4343-B4F1-284C62E3B8DB Q40476281-DF2058D7-DBF4-437E-BF61-CCCB750745B8 Q40697349-F9079A84-82C5-47B1-87B8-0833BF92FDBA

P2860

Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.

http://www.wikidata.org/entity/Q34233774

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Fosfomycin/tobramycin for inha ...... pseudomonas airway infection.

@ast

Fosfomycin/tobramycin for inha ...... pseudomonas airway infection.

@en

Fosfomycin/tobramycin for inha ...... pseudomonas airway infection.

@nl

type

label

Fosfomycin/tobramycin for inha ...... pseudomonas airway infection.

@ast

Fosfomycin/tobramycin for inha ...... pseudomonas airway infection.

@en

Fosfomycin/tobramycin for inha ...... pseudomonas airway infection.

@nl

prefLabel

Fosfomycin/tobramycin for inha ...... pseudomonas airway infection.

@ast

Fosfomycin/tobramycin for inha ...... pseudomonas airway infection.

@en

Fosfomycin/tobramycin for inha ...... pseudomonas airway infection.

@nl

P1433

Q34233774-321B6BFF-DFB5-48E8-B586-41AFBA6EF27E

P1476

Q34233774-7FBDCFE7-28D3-4415-9191-B45EF8651DE2

P2093

Q34233774-1971B844-75EE-46AC-B9BC-2943C4062513

Q34233774-2635D6E0-08EA-472A-B482-9AEAB260ECED

Q34233774-2C7FA972-5C26-4FB4-BA4F-C2C54B829422

Q34233774-4C451FEB-2C36-4C67-B284-D64719A04F77

Q34233774-50709C03-58B8-4187-889E-846E308A8605

Q34233774-67B4965A-33A9-46B3-A5D9-1858A9E97F01

Q34233774-709B4013-4384-4FF0-AE0D-0C626FB6CCC4

Q34233774-8745724A-68F3-4EC7-9189-A83BE0578000

Q34233774-F2CE8C8B-D343-42B3-BC5A-8427DEBCC092

Q34233774-F4B38792-D1E0-473C-92C5-3CB6A108A9D2

P2860

Q34233774-1D2D6FAB-88AE-4F39-A830-A709928F38C2

Q34233774-2C19C36C-B361-4736-B37D-E077D4585A6E

Q34233774-324CCF75-53A7-4D7D-8ADD-44E3681F0A9F

Q34233774-6781CBAE-88DE-4610-A706-F829062D54CB

Q34233774-6A5FD287-7DAD-430E-B61E-70409EA6AE38

Q34233774-772055AA-0CAD-4A3E-B2D4-C4DA976AA683

Q34233774-8F4884DF-C01D-416C-B683-114B55961284

Q34233774-941C461F-5B56-466F-8A34-04E6CC970AE4

Q34233774-944C9ECB-8CD0-49C0-B1FC-087C0AF3CEF9

Q34233774-96146A66-D92C-4730-AED4-67D0BD6A5FE6

P304

Q34233774-DCCC8843-1383-40FC-B3B3-3D6D62F252B1

P31

Q34233774-D2229899-F04C-4260-B590-ED046E7D5A74

P356

Q34233774-9E4849D5-5C47-4FD6-877A-C72F49EF27AB

P407

Q34233774-D4879E17-16FF-4062-8B19-5094FE017F3A

P433

Q34233774-F208E147-20DC-4159-89D1-29932D2C1B45

P478

Q34233774-DA69E0F2-1DB0-410A-9171-372D29C3FE77

P577

Q34233774-5E4B8B36-BBCF-4176-87C2-72E4194A3F96

P698

Q34233774-018EC264-A0AC-4515-ACD8-4BA97120EA9E

P921

Q34233774-4283B6C4-9413-45FF-9478-2183D1DF1E4E

P932

Q34233774-ED118B44-778A-4DCB-863E-0AA9972F418A

P356

RCCM.201105-0924OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Fosfomycin/tobramycin for inha ...... pseudomonas airway infection.

@en

P2093

A Bruce Montgomery

http://www.w3.org/2001/XMLSchema#string

Bruce C Trapnell

http://www.w3.org/2001/XMLSchema#string

Dana G Kissner

http://www.w3.org/2001/XMLSchema#string

David E Geller

http://www.w3.org/2001/XMLSchema#string

Jonathan M Rosen

http://www.w3.org/2001/XMLSchema#string

Lisa Moorehead

http://www.w3.org/2001/XMLSchema#string

Mark W Rolfe

http://www.w3.org/2001/XMLSchema#string

Matthew McKevitt

http://www.w3.org/2001/XMLSchema#string

Phase 2 FTI Study Group

http://www.w3.org/2001/XMLSchema#string

Susanna A McColley

http://www.w3.org/2001/XMLSchema#string

P2860

Spirometric reference values from a sample of the general U.S. population

Standardisation of spirometry

Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis.

Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria.

Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.

In vitro activity of fosfomycin in combination with various antistaphylococcal substances.

Pathophysiology and management of pulmonary infections in cystic fibrosis.

An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.

New antimicrobial strategies in cystic fibrosis.

Macromolecular mechanisms of sputum inhibition of tobramycin activity.

P304

171-178

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.201105-0924OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

185

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22095545

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

P932

3361752

http://www.w3.org/2001/XMLSchema#string